Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.50 |
| ▸ | FAAH | O00519 | 4/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6238894 | 1.00 | CASP2 (0.51) | CASP2EPHX2FAAHNAAADNM1 | |
| SCHEMBL12134883 | 1.00 | CASP2 (0.51) | CASP2EPHX2FAAHNAAADNM1 | |
| SCHEMBL6237083 | 0.96 | CASP2 (0.53) | CASP2EPHX2FAAHNAAADNM1 | |
| SCHEMBL6239067 | 0.96 | CASP2 (0.53) | CASP2EPHX2FAAHNAAADNM1 | |
| SCHEMBL16289831 | 0.96 | CASP2 (0.53) | CASP2EPHX2FAAHNAAADNM1 | |
| SCHEMBL28221663 | 0.96 | CASP2 (0.53) | CASP2EPHX2FAAHNAAADNM1 | |
| SCHEMBL29411282 | 0.96 | CASP2 (0.53) | CASP2EPHX2FAAHNAAADNM1 | |
| SCHEMBL6238094 | 0.93 | CASP2 (0.53) | CASP2EPHX2FAAHNAAADNM1 | |
| SCHEMBL12761238 | 0.92 | CASP2 (0.54) | CASP2EPHX2FAAHNAAADNM1 | |
| SCHEMBL28221043 | 0.92 | CASP2 (0.54) | CASP2EPHX2FAAHNAAADNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2813854-B1 | HEMOLYSIS REAGENT COMPOSITION FOR HEMOGLOBIN A1C QUANTITATIVE ANALYSIS USING ENZYMATIC METHOD | I SENS INC (KR) | 2016-09-07 | — | — | EP | claimed |
| US-9435792-B2 | Hemolysis reagent composition for hemoglobin A1C quantitative analysis using enzymatic method | I-SENS, INC. (KR) | 2016-09-06 | — | — | US | claimed |
| US-20140370539-A1 | HEMOLYSIS REAGENT COMPOSITION FOR HEMOGLOBIN A1C QUANTITATIVE ANALYSIS USING ENZYMATIC METHOD | I-Sens,Inc. a corporation | 2014-12-18 | — | — | US | claimed |
| EP-2813854-A1 | HEMOLYSIS REAGENT COMPOSITION FOR HEMOGLOBIN A1C QUANTITATIVE ANALYSIS USING ENZYMATIC METHOD | i-Sens, Inc. (KR) | 2014-12-17 | — | — | EP | claimed |
| US-11262365-B2 | Kit for hemoglobin A1C quantitative analysis | I-SENS, INC. (KR) | 2022-03-01 | — | — | US | disclosed |
| US-10702603-B2 | Methods and compositions for inactivating enveloped viruses | BIOGEN MA INC. (US) | 2020-07-07 | — | — | US | disclosed |
| EP-3527669-B1 | KIT FOR HEMOGLOBIN A1C QUANTITATIVE ANALYSIS | I SENS INC (KR) | 2020-04-29 | — | — | EP | disclosed |
| EP-3527669-A1 | KIT FOR HEMOGLOBIN A1C QUANTITATIVE ANALYSIS | i-Sens, Inc. (KR) | 2019-08-21 | — | — | EP | disclosed |
| US-20190242910-A1 | KIT FOR HEMOGLOBIN A1C QUANTITATIVE ANALYSIS | I-SENS, INC. (KR) | 2019-08-08 | — | — | US | disclosed |
| US-20190175738-A1 | METHODS AND COMPOSITIONS FOR INACTIVATING ENVELOPED VIRUSES | BIOGEN MA INC. (US) | 2019-06-13 | — | — | US | disclosed |
| EP-2879691-B1 | METHODS FOR INACTIVATING ENVELOPED VIRUSES | BIOGEN MA INC (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3456352-A1 | METHODS FOR INACTIVATING ENVELOPED VIRUSES | Biogen MA Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| US-9435792-B2 | Hemolysis reagent composition for hemoglobin A1C quantitative analysis using enzymatic method | I-SENS, INC. (KR) | 2016-09-06 | — | — | US | disclosed |
| US-9435792-B2 | Hemolysis reagent composition for hemoglobin A1C quantitative analysis using enzymatic method | I-SENS, INC. (KR) | 2016-09-06 | — | — | US | disclosed |
| US-20150330986-A1 | COMPOSITIONS FOR ENHANCING CHEMILUMINESCENCE AND METHODS OF USING THE SAME | ABBOTT LAB (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150306223-A1 | METHODS AND COMPOSITIONS FOR INACTIVATING ENVELOPED VIRUSES | BIOGEN IDEC MA INC. (US) | 2015-10-29 | — | — | US | disclosed |
| US-20140370539-A1 | HEMOLYSIS REAGENT COMPOSITION FOR HEMOGLOBIN A1C QUANTITATIVE ANALYSIS USING ENZYMATIC METHOD | I-Sens,Inc. a corporation | 2014-12-18 | — | — | US | disclosed |
| US-20140370539-A1 | HEMOLYSIS REAGENT COMPOSITION FOR HEMOGLOBIN A1C QUANTITATIVE ANALYSIS USING ENZYMATIC METHOD | I-Sens,Inc. a corporation | 2014-12-18 | — | — | US | disclosed |
| EP-2813854-A1 | HEMOLYSIS REAGENT COMPOSITION FOR HEMOGLOBIN A1C QUANTITATIVE ANALYSIS USING ENZYMATIC METHOD | i-Sens, Inc. (KR) | 2014-12-17 | — | — | EP | disclosed |
| EP-2813854-A1 | HEMOLYSIS REAGENT COMPOSITION FOR HEMOGLOBIN A1C QUANTITATIVE ANALYSIS USING ENZYMATIC METHOD | i-Sens, Inc. (KR) | 2014-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150330986-A1 | COMPOSITIONS FOR ENHANCING CHEMILUMINESCENCE AND METHODS OF USING THE SAME | APOB, MPO, LPO | CASP2 2411/4885EPHX2 313/4885FAAH 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.